
- Mount Sinai Doctors
- Treats Adults
- Video Visit Available
- Accepting New Patients
John O Mascarenhas, MD
Internal Medicine, Hematology-Oncology, Cancer (Oncology)
About Me
Dr. John Mascarenhas is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, Director of the Center of Excellence for Blood Cancers and Myeloid Disorders, and a member of The Tisch Cancer Institute. He directs the Adult Leukemia Program and leads clinical investigation within the Myeloproliferative Disorders Program. As a clinical investigator in malignant hematology with a focus on translational research involving myeloproliferative neoplasms (MPNs) and evolution to acute myeloid leukemia (AML), Dr. Mascarenhas evaluates rationale-based novel therapies for patients with MPNs and AML.
Dr. Mascarenhas is Principal Investigator (PI) of the clinical trials project within the National Cancer Institute-sponsored Myeloproliferative Neoplasms Research Consortium. He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early- and late-phase clinical trials evaluating innovative approaches to the treatment of MPNs and AML. Additionally, he holds multiple administrative roles at Mount Sinai—he is Chair of the Leukemia Disease Management Team, Co-Chair of the Hematologic Malignancy Disease Focus Group, and a full member of the Tisch Cancer Institute Protocol and Review Monitoring Committee.
Language
English, Spanish
Position
PROFESSOR | Medicine, Hematology and Medical Oncology
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
Clinical Focus
- Acute Myelogenous Leukemia—Adult
- Anemia
- Aplastic Anemia
- Biopsy
- Blood Transfusion
- Chronic Myelocytic Leukemia
- Eosinophilia
- Myelodysplastic Syndromes
- Primary Polycythemia
Education
MD, New York Medical College
Residency, Internal Medicine
Rhode Island Hospital
Fellowship, Hematology
Mount Sinai Hospital
Certifications
American Board of Internal Medicine
Awards
2010
Richard E. Rosenfeld Faculty Achievement Award
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - HealthPlus Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Magnacare-Health Care
- Medicare - NJ
- Medicare - NY
- Metroplus
- Multiplan PHCS
- NJ Medicaid
- NY Medicaid
- Oscar
- Oxford - Freedom and Liberty
- Partners Health Plan
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VNSNY Select Health Medicaid
- VillageCareMax
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms. Prithviraj Bose, Zhijian Xiao, Hans C. Hasselbalch, Josef T. Prchal, Minghui Duan, Abdulraheem Yacoub, Raajit Rampal, Jean Jacques Kiladjian, Gabriela S. Hobbs, Tsewang Tashi, Kazuya Shimoda, Keita Kirito, Harinder Gill, Hsin An Hou, Sung Eun Lee, Jian Huang, Bing Li, Albert Qin, Lennex Hsueh Lin Yu, John O. Mascarenhas, Ruben A. Mesa. Current Hematologic Malignancy Reports
- Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. Raajit K. Rampal, Sebastian Grosicki, Dominik Chraniuk, Elisabetta Abruzzese, Prithviraj Bose, Aaron T. Gerds, Alessandro M. Vannucchi, Francesca Palandri, Sung Eun Lee, Vikas Gupta, Alessandro Lucchesi, Stephen T. Oh, Andrew T. Kuykendall, Andrea Patriarca, Alberto Álvarez-Larrán, Ruben Mesa, Jean Jacques Kiladjian, Moshe Talpaz, Joseph M. Scandura, David Lavie, Morgan Harris, Sarah Katharina Kays, Qing Li, Rainer Boxhammer, Barbara Brown, Anna Maria Jegg, Claire N. Harrison, John Mascarenhas. Nature Medicine
- Fedratinib in 2025 and beyond: indications and future applications. Alexander Coltoff, John Mascarenhas. Blood advances
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Mascarenhas during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Bristol-Myers Squibb
- GSK plc.
- Swedish Orphan Biovitrum AB
- Karyopharm Inc.
- Incyte Corporation
- Pfizer Pharmaceuticals
- AbbVie Inc.
- Novartis
- F. Hoffman-La Roche Ltd.
- Blueprint Medicines
- Geron Corporation
- PharmaEssentia
- Sumitomo Pharmaceuticals, Osaka,Japan
- Kartos
- Italfarmaco S.p.A.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.